The therapeutic management of bleeding and thrombotic disorders complicating CNS malignancies

Current Treatment Options in Oncology

Volumn 13, Issue 4, 2012, Pages 451-464

  Strowd III, Roy E ^a   Knovich, Mary Ann ^a   Lesser, Glenn J ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Anticoagulation; Argatroban; Bevacizumab; Brain tumor; Central nervous system; Deep vein thrombosis; Fondaparinux; Inferior vena cava filter; Lepirudin; Malignant glioma; Pulmonary embolism; Unfractionated heparin I Low molecular weight heparin; Venous thromboembolism; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; ARGATROBAN; BEVACIZUMAB; BIOLOGICAL MARKER; CARBAMAZEPINE; CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR; D DIMER; DABIGATRAN; DALTEPARIN; DROTRECOGIN; ENOXAPARIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FONDAPARINUX; HEPARIN; IRINOTECAN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PHENYTOIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; RIVAROXABAN; TEMOZOLOMIDE; THROMBIN INHIBITOR; TINZAPARIN; UNINDEXED DRUG; WARFARIN;

ARTICLE; BLEEDING; BOLUS INJECTION; BRADYCARDIA; BRAIN HEMORRHAGE; CENTRAL NERVOUS SYSTEM TUMOR; COMPRESSION STOCKING; COMPRESSION THERAPY; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; CRANIOTOMY; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE PREDISPOSITION; DOPPLER ECHOGRAPHY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; GLIOBLASTOMA; HUMAN; HYPERCOAGULABILITY; HYPOTENSION; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; INTRAPARENCHYMAL HEMORRHAGE; INTRATUMORAL BLEEDING; LONG TERM CARE; LUNG EMBOLISM; NAUSEA; PATHOPHYSIOLOGY; PATIENT COUNSELING; PATIENT MONITORING; PERIOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; POSTTHROMBOSIS SYNDROME; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT DISEASE; RISK REDUCTION; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; UNSPECIFIED SIDE EFFECT; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; GLIOBLASTOMA; GLIOMA; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDINS; HUMANS; PIPECOLIC ACIDS; POLYSACCHARIDES; POSTOPERATIVE COMPLICATIONS; PULMONARY EMBOLISM; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; VENA CAVA FILTERS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS; WARFARIN;

EID: 84870846030     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-012-0207-3     Document Type: Article

References (46)

1. Dietcher SR. Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis. 2003;16:21-31.
2. Sorenson HT, Mellemkjaer L, Olsen JH, Baron JH. Prognosis of cancers associated with venous thromboembolism. N Eng J Med. 2000;343:1846-50.
3. Levi AD, Wallace MC, Bernstein M, Walters BC. Venous thromboembolism after brain tumor surgery: a retrospective review. Neurosurgery. 1991;28:859-63.
4. Sawaya R, Zuccarello M, Elkalliny M, Nishiyama H. Postoperative venous thromboembolism and brain tumors: part I. J Neurooncol. 1992;14:119-25.
5. Semrad TJ, O'Donnell R, Wun T, Chew H, Harvey D, Zhou H, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106:601-8.
6. Cage TA, Lamborn KR, Ware ML, Frankfurt A, Chakalain L, Berger MS, et al. Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative hemorrhage in patients with meningiomas. J Neurooncol. 2009;93(1):151-6.
7. Brandes A, Scelzi E, Salmistararo G, et al. Incidence of risk of thromboembolism during treatment of highgrade gliomas: a prospective study. Eur J Cancer. 1997;33:1592-6.
8. Simanek R, Vormittag R, Hassler M, Roessler K, Schwarz M, Zielinski C, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol. 2007;9:89-95.
9. Streiff MB, Segal J, Grossman SA, Kickler TS, Weir EG. ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer. 2004;100:1717-23.
10. Rodas TA, Fenstermaker RA, McKeever PE, Blaivas M, Dickinson LD, Papadopoulos SM, et al. Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: a preliminary report. J Neurosurg. 1998;89:200-5.
11. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol. 1983;13:334-6.
12. Thoron L, DeAngelis LM. Thromboembolic disease in primary CNS lymphoma. Proc Am Soc Clin Oncol. 10:A3811.
13. Komrokji RS, Uppal NP, Khorana AA, Lyman GH, Kaplan KL, Fisher RI, et al. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006;47(6):1029-33.
14. Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer bymeasuring Thrombosis Study. J Clin Oncol. 2011;29:2099-103.
15. Milsom CC, Yu JL, Mackman N, et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res. 2008;68:100068-76.
16. Rong Y, Belozerov VE. Tucker-Burden, et al. Epidermal growth factor receptor and PTENmodulate tissue factor expression in glioblastoma through JunD/Activator Protein-1 transcriptional activity. Cancer Res. 2009;69:2540-3549.
17. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27:4124-9.
18. Hoke M, Dieckmann K, Koppensteiner, et al. Prognostic value of plasma D-dimer levels in patients with glioblastoma multiforme -Result from a pilot study. Wien Klin Wochenschr. 2011;123:199-203.
19. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-7.
20. Beck-Razi N, Kuzmin A, Koren D, et al. Asymptomatic deep vein thrombosis in advanced cancer patients: the value of venous sonography. J Clin Ultrasound. 2010;38(5):232-7.
21. Segal JB, Eng J, Tamariz LJ, Bass EB. Review of evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med. 2007;5(1):63-73.
22. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5 (4):692-9.
23. Jenkins EO, Schiff D, Mackman N, Key NS. Venous thromboembolism in malignant gliomas. J Thromb Haemostatis. 2009;8:221-7.
24. Levin JM, Shiff D, Loeffler JS, et al. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993;43:1111-4.
25. Wen PY, Shiff D, Kesari S, Drappatz J, et al. Medical management of patients with brain tumors. J Neurooncol. 2006;80:313-32.
26. Pan E, Tsai JS, Mitchell SB. Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients. Anticancer Res. 2009;29:4309-14.
27. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490-505.
28. Joels CS, Sing RF, Heniford BT. Complications of inferior vena cava filters. Am Surg. 2003;69(8):654-9.
29. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer. 1994;73(2):493-8.
30. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost. 2010;8(9):1959-65.
31. Perry SL, Bohlin C, Reardon DA, et al. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol. 2009;95:129.
32. Schmidt F, Faul C, Dichgans J, Weller M. Low molecular weight heparin for deep vein thrombosis in glioma patients. J Neurol. 2002;249:1409.
33. Dickson LD, Miller LD, Patel CP, Gupta SK. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery. 1998;43:1074.
34. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in prevention of venous thromboembolism after elective neurosurgery. N Eng J Med. 1998;339:80.
35. Monreal M, Zacharski L, Jimenez JA, et al. Fixed dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost. 2004;2:1311.
36. Trujillo-Santos J, Nieto JA, Ruiz-Gamietea A, et al. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res. 2010;125:S58-61.
37. Lee AY, Levine MN, Baker RI, et al. Low-molecularweight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Eng J Med. 2003;349:136-53.
38. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300:2277-85.
39. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27.(28):4733-40.
40. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16(1):269-78.
41. Nghiemphu PL, Green RM, Pope WB, et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008;10:355.
42. Goli KJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas. ASCO annual meeting proceedings part I. J Clin Oncol. 2007;25:185.
43. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol. 2009;27 (31):5255-61.
44. Ngheimphu PL, Green RM, Pope WB, et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008;355-60.
45. Bartolomeo J, Norden AD, Drappatz J, et al. Safety of concurrent bevacizumab therapy and anticoagulation in high grade glioma patients (abstract #2043). J Clin Oncol. 2010;28:190s.
46. Cerrato D, Ariano C, Fiacchino F. Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg. 1978;49:378-81.